- Home
- FORR vs YARW Comparison
FORR vs YARW Comparison
Compare FORR & YARW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FORR | YARW |
|---|---|---|
| Founded | 1983 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.7M | 111.2M |
| IPO Year | 1996 | 2018 |
Fundamental Metrics
Financial Performance| Metric | FORR | YARW |
|---|---|---|
| Price | $11.68 | $42.98 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 128.0K | 20.8K |
| Earning Date | 05-06-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.25 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.88 | $31.55 |
| 52 Week High | $12.33 | $42.50 |
Technical Indicators
Market Signals| Indicator | FORR | YARW |
|---|---|---|
| Relative Strength Index (RSI) | 71.58 | N/A |
| Support Level | $6.78 | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.74 | 0.00 |
| MACD | 0.15 | 0.00 |
| Stochastic Oscillator | 90.58 | 0.00 |
Price Performance
Historical ComparisonAbout FORR Forrester Research Inc.
Forrester Research Inc provides independent research, data, and advisory services. It operates through the following segments: The Research segment develops and delivers research, connect, and analytics products; The consulting segment includes the revenues and the related costs of the company's consulting organization, and the Events segment is engaged in developing and hosting in-person and virtual events.
About YARW Yarrow Bioscience Inc. Common Stock
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.